- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Dengue Fever Treatment R&D Comes as Disease Surges in Hot-climate Regions
NanoViricides, Inc., (Pink Sheets:NNVC), officials announced today that they have signed a Cooperative Research and Development Agreement, or CRADA, with the Walter Reed Army Institute of Research ( http://wrair-www.army.mil/ ). The joint R&D effort will focus on creating new treatments for dengue fever using NanoViricides' virus-killing nanomedicine technology. "This collaboration will leverage Walter Reed's extensive experience in dengue fever research with our unique nanoviricide™ technology platform for creating anti-viral medications," said NanoViricides' President Dr. Anil Diwan.
About NanoViricides, Inc.
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.
About the Walter Reed Army Institute of Research: http://wrair-www.army.mil/
WRAIR is the largest, most diverse, and oldest laboratory in the US Army Medical Research and Materiel Command. It conducts research on a range of issues relevant to the military, including naturally occurring infectious diseases, combat casualty care, operational health hazards, and medical defense against biological and chemical weapons. WRAIR is the Department of Defense's lead agency for infectious disease research and a crucial source of research support for medical product development.
For more information, please click here
Leo Ehrlich, 917-853-6440
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
50 years after the release of the film 'Fantastic Voyage,' science upstages fiction: Science upstages fiction with nanorobotic agents designed to travel in the human body to treat cancer August 25th, 2016
Graphene under pressure August 26th, 2016
Thomas Swan and NGI announce unique partnership July 28th, 2016
New theory could lead to new generation of energy friendly optoelectronics: Researchers at Queen's University Belfast and ETH Zurich, Switzerland, have created a new theoretical framework which could help physicists and device engineers design better optoelectronics August 23rd, 2016
Researchers watch catalysts at work August 19th, 2016